摘要:
A series of 2,2′-bipyridines or 1,10-phenanthrolines featuring alkyl groups appended in the 4,4′ positions or 4,7-positions have been prepared. There is an insulating role of the methylene spacers as the electrochemical reduction potentials of these compounds that is almost identical to that of 2,2′-bipyridine. Calculations for (CH2)nCF3 derivatives (n=0-10) describes a limit for impact of CF3 through 9-10 methylenes. From both physical and theoretical data (CH2)3(CF2)x-1CF3 alkyl groups are inductively equivalent to hydrogen. Complexes of the present invention have the formula cis-LPtCl2 where L is a 4,4′-substituted-2,2′-bipyridine or a 4,7-substituted-1,10-phenanthroline. The substituents may preferably be normal, branched and cyclic alkyl groups, alkyl groups with ether linkages, highly fluorinated alkyl group, highly fluorinated alkyl groups with ether linkages, hydroxyl terminated alkyl groups, hydroxyl-terminated alkyl groups with ether linkages and perfluorinated alkyl groups.
摘要:
Phenyl boric acid and its salts and substituent derivatives (e.g., substituted phenyl) effectively inhibit the growth of several cancer cell lines and offers utility in the treatment/prevention of cancer. The material may be applied or injected into affected areas or applied topically, especially for the treatment of cervical cancer.
摘要:
Phenyl boric acid and its salts and substituent derivatives (e.g., substituted phenyl) effectively inhibit the growth of several cancer cell lines and offers utility in the treatment/prevention of cancer. The material may be applied or injected into affected areas or applied topically, especially for the treatment of cervical cancer.
摘要:
Breast cancer cell lines selected from the group consisting of ZR-75-1 and SK-BR-3 are treated by a method comprising: identifying the presence of at least one of breast cancer cell lines ZR-75-1 and SK-BR-3 in a patient; and providing a solution of boric acid or boric acid salts to the patient in a manner that delivers boric acid or boric acid salt to breast cancer cells in the patient.